Spiroindolone analogues as potential hypoglycemic with dual inhibitory activity on α-amylase and α-glucosidase

Article abstract of DOI:10.3390/molecules24122342

Inhibition of α-amylase and α-glucosidase by specified synthetic compounds during the digestion of starch helps control post-prandial hyperglycemia and could represent a potential therapy for type II diabetes mellitus. A new series of spiroheterocyclic co

Full text of DOI:10.3390/molecules24122342

molecules
Article
Spiroindolone Analogues as Potential Hypoglycemic
with Dual Inhibitory Activity on α-Amylase
and α-Glucosidase
Mezna Saleh Altowyan 1, Assem Barakat 2,3,
and H.A. Al-Ghulikah 1
*
, Abdullah Mohammed Al-Majid 2
1
Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University,
P.O. Box 84428, Riyadh 1167, Saudi Arabia; msaltowyan@pnu.edu.sa (M.S.A.);
haaalghulikah@pnu.edu.sa (H.A.A.-G.)
Department of Chemistry, College of Science, King Saud University,
P.O. Box 2455, Riyadh 11451, Saudi Arabia; amajid@ksu.edu.sa
Department of Chemistry, Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia,
Alexandria 21321, Egypt
2
3
*
Correspondence: ambarakat@ksu.edu.sa; Tel.: +966-11467-5901; Fax: +966-11467-5992
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Received: 3 June 2019; Accepted: 21 June 2019; Published: 25 June 2019
Abstract: Inhibition of
α-amylase and α-glucosidase by specified synthetic compounds during
the digestion of starch helps control post-prandial hyperglycemia and could represent a potential
therapy for type II diabetes mellitus. A new series of spiroheterocyclic compounds bearing oxindole/
benzofuran/pyrrolidine/thiazolidine motifs were synthesized via a 1,3-dipolar cyclo-addition reaction
approach. The specific compounds were obtained by reactions of chalcones having a benzo[b]furan
scaffold (compounds 2a–f), with a substituted isatin (compounds 3a–c) and heterocyclic amino
acids (compounds 4a,b). The target spiroindolone analogues 5a–r were evaluated for their potential
inhibitory activities against the enzymes
that some of the target compounds exhibit promising
Among the tested spiroindolone analogues, the cycloadduct 5r was found to be the most active (IC50
= 22.61 0.54 M and 14.05 1.03 M) as -amylase and -glucosidase inhibitors, with selectivity
α
-amylase and
α
-glucosidase. Preliminary results indicated
α
-amylase and
α
-glucosidase inhibitory activity.
±
µ
±
µ
α
α
indexes of 0.62 and 1.60, respectively. Docking studies were carried out to confirm the binding
interaction between the enzyme active site and the spiroindolone analogues.
Keywords: spiroindolone; antidiabetic; hypoglycemic; α-amylase; α-glucosidase
1. Introduction
Diabetes is a serious disease, classified as chronic, that occurs either when the pancreas does not
produce enough insulin (a hormone that regulates blood glucose), or when the body cannot effectively
use the insulin well [
live with diabetes and this number may raise to 592 million by 2035, due to increased incidence of
adult onset diabetes (T2DM) [ ]. Increased blood glucose levels, a common effect of uncontrolled
1]. According to the World Health Organization more than 400 million people
2,3
diabetes, may, over time, lead to serious consequences, including coronary heart disease, liver damage,
retinopathy, nephropathy, strokes, and peripheral nephropathy [4].
α
-Amylase and α-glucosidase are key enzymes involve in the breakdown and intestinal absorption
of carbohydrates, respectively. Inhibition of these enzymes hampers blood glucose level increases
after consumption of carbohydrates and can be an important strategy in the management of
non-insulin-dependent diabetes mellitus (NIDDM) [
5]. α-Amylases are distributed across various
organisms and show diverse substrate specificities, while possessing a common topology formed by
Molecules 2019, 24, 2342; doi:10.3390/molecules24122342
www.mdpi.com/journal/molecules

Molecules 2019, 24, 2342
2 of 20
three domains, one of which being a typical
α
-
β
barrel. Inhibition of insects’
α
-amylase is a proposed
crop protection method. On the other hand, inhibition of mammalian α-amylase is a proven therapeutic
approach in diabetes and related disorders [6]. As diabetes affects about 5% of the global population,
the management of diabetes without any side effects is still a challenge to the medical community,
and the investigation on agents for this purpose has become more important and researchers are
competing to find the new effective and safe therapeutic agents for the treatment of diabetes [7–12].
Benzofuran and its analogues are important core structures for drug discovery, showing excellent
pharmacological activity like antiviral [13], anticancer [14], anti-inflammatory [15], antihyperlipidemic [16],
anti-Alzheimer’s [17], anticonvulsant [18], antitubercular [19], CNS regulatory [20], analgesic [21], enzyme
inhibition [22,23], antipyretic activities [24].
On the other hand spiroheterocyclic compounds based on the oxindole scaffold have gain much
attention, as they exhibit pharmaceutical activity which makes them promising lead compounds for
drug discovery. Numerous biological activities have been reported for these compounds, including
anti-inflammatory, antitumor (as tyrosine kinase inhibitors), antiviral, antibacterial, DMD2-p53 protein
interaction inhibitory, and local anaesthetic activities [25–35]. One approach to discovering new drugs
is to combine different pharmacophores like benzofuran, pyrrolidine, thiazolidine and spiroxindole
systems into one hybrid target molecule and then study the biological activity. In continuation
of our research program to find novel pharmaceutical agents, we now describe the synthesis of
oxindole/benzofuran/pyrrolidine/thiazolidine analogues as new potential α-amylase, and α-glucosidase
inhibitors Figure 1.
Figure 1. Representative examples of spirooxindoles, benzo[b]furan scaffolds, acarbose as standard
drug and our designed compounds.
2. Results
Synthesis of Compounds 5a–r
Equimolar amounts of benzofuran-based chalcones 2a–f were reacted with substituted isatins
2a–c and heterocyclic amino acids 4a,b in the presence of MeOH as a solvent to give cycloadduct
in a one pot reaction [36–39] (Scheme 1). After completion of the reaction either the cycloadduct
product precipitated (just simple filtration being needed, followed by washing with 1 mL of MeOH) or
the solvent was removed and the crude product subjected to column chromatography for purification
to give the target compounds (Table 1).

Molecules 2019, 24, 2342
3 of 20
Scheme 1. The synthesized compounds 5a–r.
Table 1. Synthesized pirooxindoles and benzo[b]furan scaffolds 5a–r and their biological activity.
α-Amylase
α-Glucosidase
α-Amylase
α-Glucosidase
Compound
#
Selectivity b
Selectivity c
IC50 (µM ± SD) a
1
693.22 ± 0.10
465.12 ± 0.12
0.67
1.49
5a
2
747.08 ± 0.34
545.01 ± 1.09
0.72
1.37
5b
3
718.00 ± 0.27
585.11 ± 0.02
0.81
1.22
5c

Molecules 2019, 24, 2342
4 of 20
Table 1. Cont.
α-Amylase
α-Glucosidase
α-Amylase
α-Glucosidase
Compound
#
Selectivity b
Selectivity c
IC50 (µM ± SD) a
4
5
6
7
8
728.13 ± 0.28
710.07 ± 0.10
670.14 ± 0.10
690.09 ± 0.06
589.04 ± 0.25
549.17 ± 1.06
554.12 ± 1.42
534.04 ± 1.09
554.12 ± 1.42
494.10 ± 0.04
0.75
0.78
0.79
0.80
0.83
1.32
5d
5e
5f
1.28
1.25
1.24
1.19
5g
5h

Molecules 2019, 24, 2342
5 of 20
Table 1. Cont.
α-Amylase
α-Glucosidase
α-Amylase
α-Glucosidase
Compound
#
Selectivity b
Selectivity c
IC50 (µM ± SD) a
9
779.08 ± 0.51
39.02 ± 1.73
49.28 ± 1.09
558.07 ± 0.18
684.12 ± 0.35
29.20 ± 0.33
39.10 ± 0.54
414.12 ± 0.52
0.87
0.74
0.79
0.74
1.13
5i
10
11
12
1.33
1.26
1.37
5j
5k
5l

Molecules 2019, 24, 2342
6 of 20
Table 1. Cont.
α-Amylase
α-Glucosidase
α-Amylase
α-Glucosidase
Compound
#
Selectivity b
Selectivity c
IC50 (µM ± SD) a
13
95.26 ± 0.27
69.11 ± 0.34
0.72
1.37
5m
14
185.23 ± 1.06
98.23 ± 1.24
0.53
1.88
5n
15
115.42 ± 0.07
68.18 ± 1.54
0.59
1.69
5o
16
488.02 ± 1.11
392.13 ± 1.07
0.80
1.24
5p
17
37.22 ± 1.49
26.29 ± 0.45
0.70
1.41
5q

Molecules 2019, 24, 2342
7 of 20
Table 1. Cont.
α-Amylase
α-Glucosidase
α-Amylase
α-Glucosidase
Compound
#
Selectivity b
Selectivity c
IC50 (µM ± SD) a
N
HN
O
18
O
O
22.61 ± 0.54
0.75 + 0.07
14.05 ± 1.03
2.35 + 0.13
0.62
1.60
NH2
Acarbose (µM)
-Amylase and
5r
STD
3.13
0.31
a
α
α
-glucosidase inhibitory activity is expressed as the mean
±
SD of triplicate experiments.
b
c
Selectivity for -amylase is defined as IC50
α
(
α
-glucosidase)/IC50
(α
-amylase). Selectivity for -glucosidase is
α
defined as IC50 (α-amylase)/IC50 (α-glucosidase).
The regio- and diastereoselectivity of the formed products were previously established by X-ray
crystallography of the product from a similar reaction [36] and can be explained by the mechanism
depicted in Scheme 2. Initially, an azomethine ylide intermediate is formed by the reaction of the
heterocyclic amino acid with isatin, followed by elimination of CO2. The approach of the chalcone
towards this azomethine ylide intermediate (Path A and B) and the double bond geometry of the
azomethine (Path D and C) determine the regioselectivity and diastereoselectivity of the reaction,
respectively, according to reported literature [33–38].
Scheme 2. Plausible mechanism of formation of the target compounds 5a–r.

Molecules 2019, 24, 2342
8 of 20
3. Discussion
3.1. In Vitro Biological Activity Evaluation
The treatment of hyperglycaemia is crucial in the management of metabolic syndromes such as
type II diabetes [40]. -Amylase, and -glucosidase as digestive enzymes play an essential role in the
α
α
glucose release process, by taking part in the hydrolysis of dietary polysaccharides. These enzymes
have important roles in diabetes research, because they are potential targets for antidiabetic drugs.
Managing hyperglycaemia by the inhibition of α-amylase and α-glucosidase is a commonly accepted
treatment strategy. The inhibition of these enzymes postpones remarkably the adsorption of glucose
along with the postprandial hyperglycaemia. Acarbose is a widely applied antidiabetic drug that
inhibits pancreatic α-amylase and intestinal α-glucosidase enzymes [41]. Although it is very effective,
it has several unpleasant gastrointestinal side effects. This is the reason that there is an increased
demand for new molecules possessing less side effects.
Table 1 summarizes the different spirooxindoles and benzo[b]furan scaffolds 5a–r tested for
α
-amylase and
5j 5k 5q, and 5r which inhibit the enzyme
37.22 + 1.49 and 22.61 + 0.54 M, respectively. Interestingly the same compounds 5j
inhibit the enzyme -glucosidase with IC50 values of 29.20 + 0.33, 39.10 + 0.54, 26.29 + 0.45 and
14.05 + 1.03 µM, respectively. Compound 5r carrying an amino group on the aryl ring showed better
-amylase and -glucosidase inhibitory activity with IC50 values of 22.61 + 0.54 and 14.05 + 1.03
and selectivity indexes of 0.62 and 1.60, respectively, compared to acarbose, with an IC50 M) value
of 0.75 + 0.07 and 2.35 + 0.13 and selectivity index of 3.13 and 0.31 for -amylase and -glucosidase
inhibitory activity, respectively. In general, spirooxindoles and benzo[b]furan scaffolds 5a–r are selective
for -glucosidase and show moderate to good activities ranging from 14.05 + 1.03 to 684.12 + 0.35 M,
α
-glucosidase inhibitory activity. The most active members this series were compounds
-amylase with IC50 values of 39.02 + 1.73, 49.28 + 1.09
5k 5q, and 5r
,
,
α
,
µ
,
,
α
α
α
µM
(
µ
α
α
α
µ
with selectivity indexes ranging from 1.88 to 1.13.
3.2. Docking Study
In order to understand the binding mode of these spiro compounds and identify the important
pharmacophore(s), the molecules that exhibited potential -glucosidase and amylose inhibition were
α
subjected to docking studies using molecular modeling tools. Docking calculations were carried out
using the Openeye software [42]. The crystal structure of the target protein was obtained from the
Protein Data Bank (ID: 4uac) [42].
Compound 5r, with best consensus score of 1, docked with formation of a hydrogen bond (HB) with
TRP: 193 A through the oxoindole oxygen. The oxygen of the benzofuran ring also formed a HB with
ASN 191 A. Moreover, the pose of this compound showed that both the oxindole and benzofuran ring
oxygens adopted a single direction toward the receptor cleft (in cisoid positions, Figure 2). Meanwhile
compounds 5k, 5q, and 5j with consensus scores of 4, 9, and 10, respectively, adopted a pose where
both the oxygen of the benzofuran and the oxygen of the oxindole are in a transoid form (forming HBs
with Ser 87:A and THR387:A, respectively) and all of them overlay on each other (Figure 3).

Molecules 2019, 24, 2342
9 of 20
Figure 2. Vida visualization representing the amino acids in the binding site of the active site (ID:
4UAC) that interact with ligand 5r.
Figure 3. Vida visualization showing how all compounds 5k, 5q, and 5j overlay with each other
in transoid form in the receptor cleft.

Molecules 2019, 24, 2342
10 of 20
4. Materials and Methods
4.1. General Information
AllthechemicalswerepurchasedfromSigma-Aldrich(Riedstraße, Germany), Fluka(Buchs,Switzerland),
etc, and were used without further purification, unless otherwise stated. All melting points were measured
on a Gallenkamp melting point apparatus (Bibby Scientific Limited, Beacon Road, Stone, Staffordshire, UK)
in open glass capillaries and are uncorrected. IR Spectra were measured as KBr pellets on a 6700 FT-IR
spectrophotometer (Thermo Fisher Scientific, Madison, WI, USA). The NMR spectra (1H-NMR at 400 MHz,
and 13C-NMR at 100 MHz) were recorded on a Mercury Jeol 400 NMR spectrometer (Tokyo, Japan). Spectra
were run in deuterated chloroform (CDCl3). Chemical shifts (δ) are referred in terms of ppm and coupling
constants (J) are given in Hz. Mass spectra were recorded on a JMS-600 H system (Santa Clara, CA, USA).
Elemental analyses were carried out on a model 2400 Elemental Analyzer (Perkin Elmer, Waltham, MA, USA)
in CHN mode.
4.2. General Procedure for the Synthesis of Chalcones 2a–f (GP1)
The chalcones 2a–f were synthesized following a reported procedure [36] via addition of an aqueous
solution of NaOH to a mixture of an acetophenone derivative (1 equiv.) and a benzofuran carbaldehyde
(1 equiv.) in ethanol. The final chalcones were precipitated as yellow color powders.
(E)-3-(Benzofuran-2-yl)-1-phenylprop-2-en-1-one (2a)
Compound 2a was synthesized according to the general procedure GP1 from an equimolar
1
mixture of acetophenone (3 mmol, 360 mg) and benzofurancarbaldehyde (3 mmol, 438 mg). H-NMR
(CDCl3)
δ: 6.96 (s, 1H, CH=CH), 7.18 (t, 2H, J = 7.2 Hz, Ar-H), 7.31 (t, 2H, J = 8.0 Hz, Ar-H), 7.44(t,
2H, J = 8.0 Hz, Ar-H), 7.52(t, 2H, J = 6.8 Hz, Ar-H), 7.64(s, 1H, CH=CH), 8.02 (dd, 2H, J = 7.2, 1.6 Hz,
Ar-H); 13C-NMR (CDCl3)
δ: 189.5, 155.5, 153.0, 137.9, 133.0, 128.6, 128.5, 121.8, 111.4; [Anal. Calcd. for
C17H12O2: C, 82.24; H, 4.87; Found: C, 82.24; H, 4.86]; LC/MS (ESI, m/z): [M+], found 250.15, C17H12O2
for 249.08.
(E)-3-(Benzofuran-2-yl)-1-(4-fluorophenyl)prop-2-en-1-one (2b)
Compound 2b was synthesized according to the general procedure GP1 by reaction of equimolar
amounts of 4-fluoroacetophenone (3 mmol, 414 mg) and benzofurancarbaldehyde (3 mmol, 438 mg).
1H-NMR (CDCl3)
δ
: 6.97 (s, 1H, CH=CH), 7.13 (t, 2H, J = 7.2 Hz, Ar-H), 7.19 (t, 1H, J = 8.0 Hz, Ar-H),
7.32 (t, 1H, J = 8.0 Hz, Ar-H), 7.45 (d, 1H, J = 8.0 Hz, Ar-H), 7.54 (d, 1H, J = 8.0 Hz, Ar-H), 7.62 (d, 2H, J
= 2.8 Hz, Ar-H), 8.06–8.03 (m, 2H, Ar-H & CH=CH); 13C-NMR (CDCl3)
: 187.8, 167.0, 164.5, 155.6,
δ
152.9, 134.3, 131.0, 128.5, 123.5, 121.9, 121.4, 116.0, 111.4; [Anal. Calcd. for C17H11FO2: C, 76.68; H, 4.16;
Found: C, 76.75; H, 4.21]; LC/MS (ESI, m/z): [M+], found 268.22, C17H11FO2 for 267.07.
(E)-3-(Benzofuran-2-yl)-1-(4-bromophenyl)prop-2-en-1-one (2c)
Compound 2c was synthesized according to the general procedure GP1 by reaction of equimolar
amounts of 4-bromoacetophenone (3 mmol, 594 mg) and benzofurancarbaldehyde (3 mmol, 438 mg).
1H-NMR (CDCl3)
δ
: 7.04 (s, 1H, CH=CH), 7.25 (t, 1H, J = 7.6 Hz, Ar-
H), 7.40 (t, 1H, J = 8.0 Hz, Ar-H),
7.52(d, 1H, J = 8.8 Hz, Ar-H), 7.92–7.59 (m, 5H), 7.95 (dd, 2H, J = 7.2, 1.6 Hz, Ar-H); 13C-NMR (CDCl3)
δ
: 183.3, 156.6, 152.8, 136.6, 131.9, 131.2, 130.0, 128.4, 128.1, 126.8, 123.4, 121.9, 121.1, 112.9, 111.3; [Anal.
Calcd. for C17H11BrO2: C, 62.41; H, 3.39; Found: C, 62.48; H, 3.39]; LC/MS (ESI, m/z): [M+], found
328.05, C17H11BrO2 for 326.99.
(E)-3-(Benzofuran-2-yl)-1-(4-(trifluoromethyl)phenyl)prop-2-en-1-one (2d)
Compound 2d was synthesized according to the general procedure GP1 by reaction of equimolar
amounts of 4-(trifluoromethyl)acetophenone (3 mmol, 564 mg) and benzofuran- carbaldehyde (3 mmol,
1
438 mg). H-NMR (CDCl3)
δ: 7.16 (s, 1H, CH=CH), 7.20(t, 1H, J = 7.2 Hz, Ar-H), 7.33(t, 1H, J = 7.6 Hz,

Molecules 2019, 24, 2342
11 of 20
Ar-H), 7.46(d, 1H, J = 8.0 Hz, Ar-H), 7.56(t, 1H, J = 7.2 Hz, Ar-H), 7.65(d, 1H, J = 14.0 Hz, Ar-H),
7.72–7.69(m, 3H), 8.11 (dd, 2H, J = 8.0 Hz, Ar-H); 13C-NMR (CDCl3)
: 188.5, 156.7, 152.6, 140.7, 134.3,
δ
131.8, 128.8, 128.4, 127.0, 125.7, 125.7, 123.5, 122.0, 121.1, 113.3, 111.4; [Anal. Calcd. for C18H11F3O2: C,
68.36; H, 3.51; Found: C, 68.29; H, 3.62]; LC/MS (ESI, m/z): [M+], found 318.35, C18H11F3O2 for 317.07.
(E)-3-(Benzofuran-2-yl)-1-(4-chlorophenyl)prop-2-en-1-one (2e)
Compound 2e was synthesized according to the general procedure GP1 by reaction of equimolar
amounts of 4-chloroacetophenone (3 mmol, 462 mg) and benzofurancarbaldehyde (3 mmol, 438 mg).
1H-NMR (CDCl3)
δ
: 6.98 (s, 1H, CH=CH), 7.19 (t, 2H, J = 7.2 Hz, Ar-H), 7.32 (t, 1H, J = 8.0 Hz, Ar-H),
7.43(t, 1H, J = 8.0 Hz, Ar-H), 7.55 (d, 1H, J = 8.0 Hz, Ar-H), 7.63 (d, 1H, J = 8.0 Hz, Ar-H), 7.62 (d, 2H, J
= 2.8 Hz, Ar-H), 7.97 (m, 2H, Ar-H & CH=CH); 13C-NMR (CDCl3)
: 188.2, 155.6, 152.8, 139.5, 136.2,
δ
131.3, 129.9, 129.0, 128.5, 126.9, 123.5, 121.9, 121.3. 112.9, 111.4; [Anal. Calcd. for C17H11ClO2: C, 72.22;
H, 3.92; Found: C, 72.31; H, 4.01]; LC/MS (ESI, m/z): [M+], found 284.18, C17H11ClO2 for 283.04.
(E)-1-(4-Aminophenyl)-3-(benzofuran-2-yl)prop-2-en-1-one (2f)
Compound 2f was synthesized according to the general procedure GP1 by reaction of equimolar
amounts of 4-aminoacetophenone (3 mmol, 405 mg) and benzofurancarbaldehyde (3 mmol, 438 mg).
1H-NMR (CDCl3)
δ
: 4.14 (brs, 2H, NH2), 6.65 (d, 1H, J = 8.4 Hz, CH=CH), 6.90 (s, 1H, CH=CH),
7.19–7.15 (m, 2H, Ar-H), 7.31 (t, 1H, J = 7.6 Hz, Ar-H), 7.44 (d, 1H, J = 8.0 Hz, Ar-H), 7.52 (d, 1H, J = 7.2
Hz, Ar-H), 7.63 (d, 2H, J = 14.0 Hz, Ar-H), 7.92 (d, 2H, J = 8.0 Hz, Ar-H); 13C-NMR (CDCl3)
: 187.2,
δ
155.4, 153.4, 151.3, 131.2, 129.4, 128.6, 128.3, 126.3, 123.3, 122.1, 121.7, 113.9, 111.5, 111.3; [Anal. Calcd.
for C17H13NO2: C, 77.55; H, 4.98; N, 5.32; Found: C, 77.62; H, 5.07; N, 5.40]; LC/MS (ESI, m/z): [M+],
found 265.14, C17H13NO2 for 264.09.
4.3. General Procedure for the Synthesis of Compounds 5a–r (GP2)
A mixture of enone 2a–f (0.5 mmol), substituted isatin 3a–c (0.5 mmol) and heterocyclic amino
acids 4a,b (0.5 mmol) in methanol (10 mL) was refluxed in an oil bath for an appropriate time (1–3 h).
After completion of the reaction as evident from TLC, the solvent was removed using a rotary evaporator
and the crude product was purified by column chromatography using (EtOAc:n-hexane 2:8 → 3:7) to
affording the final compounds in pure form. In some cases the target compounds precipitated and just
simple filtration provide the desired compounds in a pure form.
(3S)-70-(Benzofuran-2-yl)-60-benzoyl-5-chloro-10,60,70,7a0-tetrahydro-30H-spiro[indoline-3,50-pyrrolo[1,2-
c]thiazol]-2-one (5a)
Compound 5a was synthesized according to the general procedure GP2 by reaction of equimolar
amounts of 2a (0.5 mmol, 124 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5 mg), and ((S)-thiazolidine-4-carboxylic
acid 4a (0.5 mmol, 66.5 mg). Yield (450 mg, 90%); white powder; m.p. 132–133 ◦C; 1H-NMR (CDCl3)
δ:
3.18–3.08 (m, 1H, CH), 3.41 (d, 1H, J = 10.8 Hz, CH), 3.66 (q, 1H, J = 7.2 Hz, CH), 3.83 (d, 1H, J = 11.2
Hz, CH), 4.12 (q, 1H, J = 12 Hz, CH), 4.51–4.47 (m, 1H, CH), 4.94 (d, 1H, J = 11.6 Hz, CH), 6.42 (d, 1H,
J = 8.8 Hz, Ar
(d, 1H, J = 2.4 Hz, Ar
132.3, 130.2, 128.9, 128.3, 128.0, 127.9, 124.6, 124.0, 122.8, 120.8, 74.5, 71.6, 59.2, 58.4, 54.9, 45.3, 36.9,
18.4; IR (KBr, cm−1
max= 3350, 3080, 2929, 2860, 1710, 1620, 1560; [Anal. Calcd. for C28H21ClN2O3S:
H
), 6.62 (s, 1H, CH=benzofuran), 7.18–7.05 (m, 65H, Ar
H), 7.42–7.29 (m, 5H, ArH), 7.55
H
); 8.07 (s, 1H, NH); 13C NMR (CDCl3)
δ
: 195.6, 179.5, 154.8, 154.5, 139.0, 136.5,
)
ν
C, 67.13; H, 4.23; N, 5.59; Found: C, 67.01; H, 4.35; N, 5.67]; LC/MS (ESI, m/z): [M+], found 502.17,
C26H19Cl2FN2O2S for 501.10.
(3S)-10-(Benzofuran-2-yl)-20-benzoyl-5-chloro-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro[indoline-3,30-
pyrrolo[2,1-a]isoindol]-2-one (5b)
Compound 5b was synthesized according to the general procedure GP2 by reaction of equimolar
amounts of 2a (0.5 mmol, 124 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5 mg), and (2S,3aS,7aS)-octahydro-
1H-indole-2-carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (477 mg, 89%); orange powder; m.p.

Molecules 2019, 24, 2342
12 of 20
120–122 ◦C; 1H-NMR (CDCl3)
δ: 0.95–0.72 (m, 5H, CHCH2CH2), 1.46–1.17 (m, 5H, CHCH2CH2),
1.84–1.71 (m, 2H, CH2), 2.09 (t, 1H, J = 5.2 Hz, CH), 3.06 (d, 1H, J = 3.6 Hz, CH), 4.01 (t, 1H, J = 10.8 Hz
CH), 4.50–4.44 (m, 1H, CH), 5.13 (d, 1H, J = 12.0 Hz, CH), 6.41 (d, 1H, J = 8.8 Hz, Ar ), 6.50 (s,
1H, CH=benzofuran), 7.18–7.01 (m, 5H, Ar ), 7.41–7.32 (m, 5H, Ar
), 8.51 (brs, 1H, NH); 13C-NMR
(CDCl3) : 195.9, 181.6, 155.5, 154.6, 138.9, 136.7, 133.2, 129.4, 128.4, 128.2, 128.0, 127.8, 127.6, 125.8,
123.6, 122.5, 120.5, 111.0, 103.5, 72.1, 67.9, 62.4, 57.6, 47.3, 41.8, 37.7, 28.1, 27.5, 24.6, 19.6; IR (KBr, cm−1
max= 3380, 3250, 3060, 2925, 2580, 1720, 1615, 1570; [Anal. Calcd. for C33H29ClN2O3: C, 73.80; H,
,
H
H
H
δ
)
ν
5.44; N, 5.22; Found: C, 73.71; H, 5.39; N, 5.02;]; LC/MS (ESI, m/z): [M+], found 538.25, C33H29ClN2O3
for 537.19.
(3S)-70-(Benzofuran-2-yl)-5-chloro-60-(4-fluorobenzoyl)-10,60,70,7a0-tetrahydro-30H-spiro[indoline-3,50-
pyrrolo[1,2-c]thiazol]-2-one (5c)
Compound 5c was synthesized according to the general procedure GP2 by reaction of equimolar
amounts of 2b (0.5 mmol, 133 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5 mg), and ((S)-thiazolidine-4-carboxylic
acid 4a (0.5 mmol, 66.5 mg). Yield (476 mg, 92%); faint yellow powder; m.p. 110–112 ◦C; 1H-NMR
(CDCl3)
1H, J = 10.4 Hz, CH), 4.47 (t, 1H, J = 8.4 Hz, CH), 4.89 (d, 1H, J = 12.0 Hz, CH), 6.51 (d, 1H, J = 8.8 Hz,
Ar ), 6.61 (s, 1H, CH=benzofuran), 6.80 (t, 1H, J = 8.8 Hz, Ar ), 7.17–7.07 (m, 4H, Ar ), 7.43–7.38 (m,
5H, Ar ), 7.56 (s, 1H, Ar : 193.9, 179.8, 166.9, 164.2, 154.8,
); 8.60 (s, 1H, NH); 13C-NMR (CDCl3)
154.2, 138.9, 132.8, 130.7, 130.6, 128.2, 128.1, 124.4, 124.2, 122.9, 122.8, 120.7, 115.6, 115.3, 111.1, 110.9,
104.7, 74.6, 71.6, 71.4, 59.1, 58.9, 45.4, 45.3, 36.9; IR (KBr, cm−1
max= 3350, 3230, 3108, 2920, 2860, 1730,
δ: 3.16–306 (m, 2H, CH2), 3.40 (d, 1H, J = 10.8 Hz, CH), 3.82 (d, 1H, J = 10.8 Hz, CH), 4.08 (t,
H
H
H
H
H
δ
)
ν
1615, 1580; [Anal. Calcd. for C28H20ClFN2O3S: C, 64.80; H, 3.88; N, 5.40; Found: C, 64.73; H, 3.79; N,
5.49]; LC/MS (ESI, m/z): [M+], found 518.09, C28H20ClFN2O3S for 519.09.
(3S)-10-(benzofuran-2-yl)-5-chloro-20-(4-fluorobenzoyl)-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro-[indoline-
3,30-pyrrolo[2,1-a]isoindol]-2-one (5d)
Compound 5d was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2b (0.5 mmol, 133 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (487 mg, 88%); white powder;
m.p. 125–127 ◦C; 1H-NMR (CDCl3)
δ
: 1.00–0.75 (m, 5H, CHCH2CH2), 1.48–1.13 (m, 5H, CHCH2CH2),
1.85–1.71 (m, 2H, CH2), 2.11 (t, 1H, J = 5.2 Hz, CH), 3.07 (d, 1H, J = 3.6 Hz, CH), 4.00 (t, 1H, J = 10.8 Hz,
CH), 4.50–4.44 (m, 1H, CH), 5.10 (d, 1H, J = 12.0 Hz, CH), 6.45 (dd, 1H, J = 8.4, 2.0 Hz, Ar ), 6.50 (s,
1H, CH=benzofuran), 6.86 (t, 1H, J = 8.8 Hz, CH), 7.18–7.04 (m, 5H, Ar ), 7.49–7.32 (m, 5H, Ar ), 8.28
(brs, 1H, NH); 13C-NMR (CDCl3)
: 194.3, 181.3, 181.2, 167.0, 164.5, 155.4, 154.7, 138.7, 133.1, 130.8,
129.5, 128.4, 127.9, 127.8, 127.6,125.8, 120.5, 115.2, 110.9, 103.5,72.1, 67.9, 62.4, 57.6, 47.3, 41.9, 37.7, 28.2,
27.5, 24.6,19.6; IR (KBr, cm−1
max = 3400, 3250, 3108, 2929, 2850, 1720, 1618, 1590; [Anal. Calcd. for
H
H
H
δ
)
ν
C33H28ClFN2O3: C, 71.41; H, 5.08; N, 5.05; Found: C, 71.49; H, 5.10; N, 5.00]; LC/MS (ESI, m/z): [M+],
found 556.33, C33H28ClFN2O3 for 555.18.
(3S)-10-(Benzofuran-2-yl)-5-bromo-20-(4-fluorobenzoyl)-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro-[indoline-
3,30-pyrrolo[2,1-a]isoindol]-2-one (5e)
Compound 5e was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2b (0.5 mmol, 133 mg), 5-Br-isatin 3b (0.5 mmol, 112 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-◦carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (500 mg, 85%); faint orange
1
powder; m.p. 125–127 C; H-NMR (CDCl3)
δ: 1.04–0.82 (m, 5H, CHCH2CH2), 1.55–1.30 (m, 5H,
CHCH2CH2), 1.93–1.80 (m, 2H, CH2), 2.18 (t, 1H, J = 5.2 Hz, CH), 3.15 (d, 1H, J = 3.6 Hz, CH), 4.10 (t,
1H, J = 10.8 Hz, CH), 4.50-4.59-4.53 (m, 1H, CH), 5.20 (d, 1H, J = 12.0 Hz, CH), 6.51 (dd, 1H, J = 8.4, 2.0
Hz, Ar
(m, 5H, Ar
133.0, 132.3, 130.7, 130.6, 130.5, 128.4, 126.1, 123.6, 122.6, 120.5, 115.4, 115.2, 114.9, 111.6, 110.9, 103.5,
72.1, 67.9, 62.3, 57.6, 47.2, 41.8, 37.6, 28.1, 27.4, 24.5, 19.5; IR (KBr, cm−1
max = 3405, 3250, 3110, 2929,
H
), 6.61 (s, 1H, CH=benzofuran), 6.94 (t, 1H, J = 8.8 Hz, CH), 7.38–7.05 (m, 5H, Ar
H), 7.58–7.39
H
), 8.82 (s, 1H, NH); 13C-NMR (CDCl3)
δ
: 194.3, 181.5, 166.9, 164.4, 155.3, 154.6, 139.3, 133.1,
)
ν

Molecules 2019, 24, 2342
13 of 20
2850, 1720, 1615, 1590; [Anal. Calcd. for C33H28BrFN2O3: C, 66.12; H, 4.71; N, 4.67; Found: C, 66.19; H,
4.78; N, 4.59]; LC/MS (ESI, m/z): [M+], found 600.35, C33H28BrFN2O3 for 599.13.
(3S)-10-(Benzofuran-2-yl)-20-(4-bromobenzoyl)-5-chloro-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro-[indoline-
3,30-pyrrolo[2,1-a]isoindol]-2-one (5f)
Compound 5f was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2c (0.5 mmol, 163 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (546 mg, 89%); white powder;
m.p. 120–121 ◦C; 1H-NMR (CDCl3)
δ
: 0.96–0.72 (m, 5H, CHCH2CH2), 1.46–1.15 (m, 5H, CHCH2CH2),
1.95–1.71 (m, 2H, CH2), 2.08 (t, 1H, J = 5.2 Hz, CH), 3.06 (d, 1H, J = 3.6 Hz, CH), 4.00 (t, 1H, J = 10.8 Hz,
CH), 4.50-4.49-4.43 (m, 1H, CH), 5.09 (d, 1H, J = 12.0 Hz, CH), 6.44 (dd, 1H, J = 8.4, 2.0 Hz, Ar ), 6.49
(s, 1H, CH=benzofuran), 7.17–7.03 (m, 4H, Ar ), 7.38–7.28 (m, 4H, Ar
), 8.41 (s, 1H, NH); 13C-NMR
(CDCl3) : 194.9, 181.3, 155.3, 154.6, 138.7, 136.3, 131.5, 129.6, 128.5, 128.3, 127.8, 127.7, 125.6, 123.6,
122.6,120.5, 111.1,111.0, 103.6, 72.1, 67.9, 62.3, 57.6, 47.2, 41.8, 37.6, 28.1, 27.4, 24.5, 19.5; IR (KBr, cm−1
max = 3415, 3259, 3080, 2930, 2855, 1730, 1615, 1585; [Anal. Calcd. for C33H28BrClN2O3: C, 64.35; H,
H
H
H
δ
)
ν
4.58; N, 4.55; Found: C, 64.41; H, 4.65; N, 4.67]; LC/MS (ESI, m/z): [M+], found 616.27, C33H28BrClN2O3
for 615.10.
(3S)-10-(Benzofuran-2-yl)-5-bromo-20-(4-bromobenzoyl)-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro-[indoline-
3,30-pyrrolo[2,1-a]isoindol]-2-one (5g)
Compound 5g has been synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2c (0.5 mmol, 163 mg), 5-Br-isatin 3b (0.5 mmol, 112 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-◦carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (522 mg, 92%); faint yellow
1
powder; m.p. 112–114 C; H-NMR (CDCl3)
δ: 1.05–0.82 (m, 5H, CHCH2CH2), 1.56–1.27 (m, 5H,
CHCH2CH2), 1.93–1.81 (m, 2H, CH2), 2.19 (t, 1H, J = 5.2 Hz, CH), 3.15 (d, 1H, J = 3.6 Hz, CH), 4.12 (t,
1H, J = 10.8 Hz, CH), 4.50-4.59-4.52 (m, 1H, CH), 5.18 (d, 1H, J = 12.0 Hz, CH), 6.51 (dd, 1H, J = 8.4,
2.0 Hz, Ar
1H, NH); 13C-NMR (CDCl3)
128.5, 128.3, 126.1, 123.6, 122.6, 120.5, 114.9, 111.1, 111.0, 103.6, 72.1, 67.9, 62.3, 57.5, 47.2, 41.8, 37.6, 28.1,
27.4, 24.5, 19.5; IR (KBr, cm−1
max = 3390, 3250, 3080, 2930, 2856, 1720, 1615, 1585; [Anal. Calcd. for
H
), 6.60 (s, 1H, CH=benzofuran), 7.34–7.15 (m, 4H, Ar
H), 7.48–7.38 (m, 4H, ArH), 8.64 (s,
δ
: 194.9, 181.2, 155.2, 154.6, 139.2, 135.3, 132.4, 131.5, 131.4, 130.5, 129.5,
)
ν
C33H28Br2N2O3: C, 60.02; H, 4.27; N, 4.24; Found: C, 60.11; H, 4.31; N, 4.15]; LC/MS (ESI, m/z): [M+],
found 660.21, C33H28Br2N2O3 for 659.05.
(3S)-70-(Benzofuran-2-yl)-5-bromo-60-(4-bromobenzoyl)-10,60,70,7a0-tetrahydro-30H-spiro[indoline-3,50-
pyrrolo[1,2-c]thiazol]-2-one (5h)
Compound 5h was synthesized according to the general procedure GP2 by reaction of equimolar
amounts of 2c (0.5 mmol, 163 mg), 5-Br-isatin 3b (0.5 mmol, 112 mg), and ((S)-thiazolidine-4-carboxylic
acid 4a (0.5 mmol, 66.5 mg). Yield (534 mg, 86%); white powder; m.p. 118–120 ◦C; 1H-NMR (CDCl3)
δ:
3.16–306 (m, 2H, CH2), 3.40 (d, 1H, J = 10.8 Hz, CH), 3.82 (d, 1H, J = 10.8 Hz, CH), 4.06 (t, 1H, J = 10.4
Hz, CH), 4.47 (t, 1H, J = 8.4 Hz, CH), 4.87 (d, 1H, J = 12.0 Hz, CH), 6.46 (d, 1H, J = 8.8 Hz, Ar ), 6.61 (s,
1H, CH=benzofuran), 7.32 -7.08 (m, 4H, Ar ), 7.42 -7.34 (m, 5H, Ar ), 7.67 (s, 1H, Ar ); 8.41 (s, 1H,
NH); 13C-NMR (CDCl3)
: 194.5, 179.4, 154.8, 154.2, 139.4, 135.1, 133.1, 131.5, 131.4, 129.4, 128.6, 128.2,
124.8, 124.1, 122.8, 120.8, 115.3, 111.4, 111.1, 104.7, 74.4, 71.5, 60.4, 59.1, 54.9, 45.3, 36.8, 29.6, 21.0, 14.1; IR
(KBr, cm−1
max = 3410, 3250, 3070, 2930, 2856, 1733, 1610, 1580; [Anal. Calcd. for C28H20Br2N2O3S:
H
H
H
H
δ
)
ν
C, 53.87; H, 3.23; N, 4.49; Found: C, 53.95; H, 3.31; N, 4.60]; LC/MS (ESI, m/z): [M+], found 624.05,
C28H20Br2N2O3S for 622.96.
(3S)-70-(Benzofuran-2-yl)-60-(4-bromobenzoyl)-5-chloro-10,60,70,7a0-tetrahydro-30H-spiro[indoline-3,50-
pyrrolo[1,2-c]thiazol]-2-one (5i)
Compound 5i was synthesized according to the general procedure GP2 by reaction of equimolar
amounts of 2c (0.5 mmol, 163 mg), 5-Br-isatin 3b (0.5 mmol, 112 mg), and ((S)-thiazolidine-4-carboxylic

Molecules 2019, 24, 2342
14 of 20
acid 4a (0.5 mmol, 66.5 mg). Yield (485 mg, 84%); faint yellow powder; m.p. 144–145 ◦C; 1H-NMR
(CDCl3) : 3.16–310 (m, 2H, CH2), 3.41 (d, 1H, J = 10.8 Hz, CH), 3.84 (d, 1H, J = 10.8 Hz, CH), 4.08 (t,
1H, J = 10.4 Hz, CH), 4.49 (t, 1H, J = 8.4 Hz, CH), 4.89 (d, 1H, J = 12.0 Hz, CH), 6.50 (d, 1H, J = 8.8 Hz,
Ar ), 6.61 (s, 1H, CH=benzofuran), 7.19 -7.09 (m, 4H, Ar ), 7.43 -7.25 (m, 5H, Ar ), 7.55 (s, 1H, Ar );
8.07 (s, 1H, NH); 13C-NMR (CDCl3)
: 194.5, 179.4, 154.8, 154.2, 138.8, 135.2, 131.6, 130.3, 129.5, 128.9,
128.7, 128.2, 128.1, 124.4, 124.1, 122.9, 120.8, 115.3, 111.1, 110.9, 104.8, 74.5, 71.5, 59.0, 55.0, 45.3, 36.9,
29.6, 21.0, 14.1; IR (KBr, cm−1
max = 3411, 3235, 3108, 2930, 2870, 1733, 1620, 1580; [Anal. Calcd. for
δ
H
H
H
H
δ
)
ν
C28H20BrClN2O3S: C, 57.99; H, 3.48; N, 4.83; Found: C, 58.08; H, 3.40; N, 4.74]; LC/MS (ESI, m/z): [M+],
found 580.16, C28H20BrClN2O3S for 579.01.
(3S)-10-(Benzofuran-2-yl)-5-chloro-20-(4-(trifluoromethyl)benzoyl)-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydro-
spiro[indoline-3,30-pyrrolo[2,1-a]isoindol]-2-one (5j)
Compound 5j was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2d (0.5 mmol, 158 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-◦carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (531 mg, 88%); faint yellow
1
powder; m.p. 120–121 C; H-NMR (CDCl3)
δ: 0.89–0.72 (m, 5H, CHCH2CH2), 1.42–1.14 (m, 5H,
CHCH2CH2), 1.97–1.73 (m, 2H, CH2), 2.06 (t, 1H, J = 5.2 Hz, CH), 3.04 (d, 1H, J = 3.6 Hz, CH), 4.02 (t,
1H, J = 10.8 Hz, CH), 4.45–4.42 (m, 1H, CH), 5.14 (d, 1H, J = 12.0 Hz, CH), 6.41 (dd, 1H, J = 8.4, 2.0 Hz,
Ar
13C-NMR (CDCl3)
122.6, 120.5, 111.1, 103.6, 72.0, 67.9, 62.6, 57.5, 47.2, 41.8, 37.6, 28.1, 27.4, 19.5; IR (KBr, cm−1
H
), 6.51 (s, 1H, CH=benzofuran), 7.16–7.04 (m, 4H, Ar
: 195.3, 181.3, 155.1, 154.6, 139.4, 138.7, 134.5, 129.6, 128.3, 127.8, 125.6, 125.1, 123.7,
max = 3400,
H), 7.48–7.31 (m, 4H, ArH), 8.42 (s, 1H, NH);
δ
)
ν
3230, 3108, 2930, 2870, 1733, 1620, 1580; [Anal. Calcd. for C34H28ClF3N2O3: C, 67.49; H, 4.66; N, 4.63;
Found: C, 67.45; H, 4.72; N, 4.60]; LC/MS (ESI, m/z): [M+], found 606.32, C34H28ClF3N2O3 for 605.17.
(3S)-10-(Benzofuran-2-yl)-5-bromo-20-(4-(trifluoromethyl)benzoyl)-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydro-
spiro[indoline-3,30-pyrrolo[2,1-a]isoindol]-2-one (5k)
Compound 5k was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2d (0.5 mmol, 158 mg), 5-Br-isatin 3b (0.5 mmol, 112 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (576 mg, 89%); yellow powder;
m.p. 123–124 ◦C; 1H-NMR (CDCl3)
δ
: 1.04–0.86 (m, 5H, CHCH2CH2), 1.56–1.29 (m, 5H, CHCH2CH2),
1.98–1.86 (m, 2H, CH2), 2.19 (t, 1H, J = 5.2 Hz, CH), 3.17 (d, 1H, J = 3.6 Hz, CH), 4.11 (t, 1H, J = 10.8 Hz,
CH), 4.58- (m, 1H, CH), 5.26 (d, 1H, J = 12.0 Hz, CH), 6.51 (dd, 1H, J = 8.4, 2.0 Hz, Ar ), 6.64 (s, 1H,
CH=benzofuran), 7.37–7.20 (m, 4H, Ar ), 7.61–7.44 (m, 4H, Ar
), 8.37 (s, 1H, NH); 13C-NMR (CDCl3)
: 195.3, 180.9, 155.0, 154.6, 139.4, 139.2, 138.7, 132.5, 130.5, 128.4, 126.0, 125.2, 123.2, 122.7, 120.6, 115.1,
111.5, 111.0, 103.7, 71.9, 67.9, 62.7, 57.5, 47.2, 41.8, 37.6, 28.1, 27.4, 19.5; IR (KBr, cm−1
= 3386, 3230,
H
H
H
δ
)
ν
max
3108, 2940, 2860, 1710, 1620, 1580; [Anal. Calcd. for C34H28BrF3N2O3: C, 62.87; H, 4.35; N, 4.31; Found:
C, 62.97; H, 4.42; N, 4.47]; LC/MS (ESI, m/z): [M+], found 650.34, C34H28BrF3N2O3 for 649.12.
(3S)-70-(Benzofuran-2-yl)-5-chloro-60-(4-(trifluoromethyl)benzoyl)-10,60,70,7a0-tetrahydro-30H-spiro-[indoline-
3,50-pyrrolo[1,2-c]thiazol]-2-one (5l)
Compound 5l was synthesized according to the general procedure GP2 by reaction of equimolar
amounts of 2d (0.5 mmol, 158 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5mg), and ((S)-thiazolidine-4-carboxylic
acid 4a (0.5 mmol, 66.5 mg). Yield (516 mg, 91%); white powder; m.p. 110–112 ◦C; 1H-NMR (CDCl3)
δ:
3.13–3.07 (m, 2H, CH2), 3.39 (d, 1H, J = 10.8 Hz, CH), 3.80 (d, 1H, J = 10.8 Hz, CH), 4.09 (t, 1H, J = 10.4
Hz, CH), 4.50 (t, 1H, J = 8.4 Hz, CH), 4.93 (d, 1H, J = 12.0 Hz, CH), 6.47 (d, 1H, J = 8.8 Hz, Ar ), 6.62 (s,
1H, CH=benzofuran), 7.17–7.07 (m, 4H, Ar ), 7.54–7.34 (m, 5H, Ar ), 7.55 (s, 1H, Ar ); 8.25 (s, 1H,
NH); 13C-NMR (CDCl3)
: 194.9, 179.3, 154.8, 154.0, 139.1, 138.9, 134.5, 134.2, 130.3, 128.8, 128.2, 128.1,
125.2, 124.6, 124.3, 124.1, 122.9, 121.9, 120.8, 111.1, 110.9, 104.8, 74.4, 71.5, 59.4, 54.9, 45.3, 36.9, 14.1; IR
(KBr, cm−1
= 3410, 3230, 3080, 2920, 2856, 1730, 1620, 1590; [Anal. Calcd. for C H ClF N O S:
H
H
H
H
δ
)
ν
max
29 20
3
2
3
C, 61.22; H, 3.54; N, 4.92; Found: C, 61.31; H, 3.64; N, 5.02]; LC/MS (ESI, m/z): [M+], found 570.14,
C29H20ClF3N2O3S for 569.08.

Molecules 2019, 24, 2342
15 of 20
(3S)-10-(Benzofuran-2-yl)-20-(4-fluorobenzoyl)-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro[indoline-3,30-
pyrrolo[2,1-a]isoindol]-2-one (5m)
Compound 5m was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2b (0.5 mmol, 133 mg), isatin 3c (0.5 mmol, 73.5 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (473 mg, 90%); white powder;
m.p. 137–138 ◦C; 1H-NMR (CDCl3) 1.04–0.78 (m, 5H, CHCH2CH2), 1.49–1.33 (m, 5H, CHCH2CH2),
1.84–1.73 (m, 2H, CH2), 2.09 (t, 1H, J = 5.2 Hz, CH), 3.09 (d, 1H, J = 3.6 Hz, CH), 4.08 (t, 1H, J = 10.8
Hz, CH), 4.52–4.46 (m, 1H, CH), 5.10 (d, 1H, J = 12.0 Hz, CH), 6.46 (dd, 1H, J = 8.4, 2.0 Hz, Ar
(s, 1H, CH=benzofuran), 7.18–6.82 (m, 4H, Ar ), 7.43–7.33 (m, 4H, Ar
), 7.66 (s, 1H, NH); 13C-NMR
(CDCl3) : 194.7, 181.0, 166.7, 164.4, 155.7, 154.8, 140.1, 133.3, 133.2, 130.8, 129.4, 128.5, 123.9,123.4,
122.6, 121.1, 115.3, 110.9, 109.9, 103.4, 71.9, 62.5, 59.4, 57.7, 47.4, 37.7, 28.8, 19.4; IR (KBr, cm−1
H), 6.49
H
H
δ
)
ν
=
max
3398, 3250, 3060, 2950, 2860, 1715, 1615, 1580; [Anal. Calcd. for C29H20ClF3N2O3S: C, 76.14; H, 5.62; N,
5.38; Found: C, 76.23; H, 5.71; N, 5.57]; LC/MS (ESI, m/z): [M+], found 522.40, C33H29FN2O3 for 521.22.
(3S)-10-(Benzofuran-2-yl)-20-(4-bromobenzoyl)-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro[indoline-3,30-
pyrrolo[2,1-a]isoindol]-2-one (5n)
Compound 5n was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2c (0.5 mmol, 163 mg), isatin 3c (0.5 mmol, 73.5 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (498 mg, 86%); white powder;
m.p. 118–120 ◦C; 1H-NMR (CDCl3) 0.98–0.79 (m, 5H, CHCH2CH2), 1.47–1.29 (m, 5H, CHCH2CH2),
1.84–1.72 (m, 2H, CH2), 2.07 (t, 1H, J = 5.2 Hz, CH), 3.08 (d, 1H, J = 3.6 Hz, CH), 4.05 (t, 1H, J = 10.8 Hz,
CH), 4.51–4.45 (m, 1H, CH), 5.09 (d, 1H, J = 12.0 Hz, CH), 6.48 (dd, 1H, J = 8.4, 2.0 Hz, Ar
CH=bnzofuran), 7.17–6.94 (m, 4H, Ar ), 7.38–7.23 (m, 4H, Ar
), 8.16 (s, 1H, NH); 13C-NMR (CDCl3)
: 195.4, 181.4, 155.7, 154.6, 140.2, 135.5, 131.5, 131.4, 131.3, 129.6, 128.4, 128.2, 127.6, 127.5, 123.8,123.5,
122.5, 122.1, 111.1, 110.1, 103.5, 71.9, 67.9, 62.3, 57.9, 57.4, 47.2, 37.7, 28.8, 24.6, 19.7; IR (KBr, cm−1
H), 6.50 (s, 1H,
H
H
δ
)
ν
max
= 3410, 3260, 3085, 2930, 2869, 1720, 1620, 1580; [Anal. Calcd. for C33H29BrN2O3: C, 68.16; H, 5.03; N,
4.82; Found: C, 68.29; H, 5.15; N, 5.01]; LC/MS (ESI, m/z): [M+], found 582.33, C33H29BrN2O3 for 581.14.
(3S)-10-(Benzofuran-2-yl)-5-chloro-20-(4-chlorobenzoyl)-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro-[indoline-
3,30-pyrrolo[2,1-a]isoindol]-2-one (5o)
Compound 5o was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2e (0.5 mmol, 141 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-◦carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (507 mg, 89%); faint yellow
1
powder; m.p. 125–126 C; H-NMR (CDCl3)
δ: 0.94–0.72 (m, 5H, CHCH2CH2), 1.46–1.13 (m, 5H,
CHCH2CH2), 1.83–1.70 (m, 2H, CH2), 2.09 (t, 1H, J = 5.2 Hz, CH), 3.05 (d, 1H, J = 3.6 Hz, CH), 4.04
(t, 1H, J = 10.8 Hz, CH), 4.49–4.43 (m, 1H, CH), 5.10 (d, 1H, J = 12.0 Hz, CH), 6.46 (dd, 1H, J = 8.4,
2.0 Hz, Ar
1H, NH); 13C-NMR (CDCl3)
127.6, 125.6, 123.7, 123.5, 122.6, 122.5, 120.5, 111.1, 110.9, 103.6, 72.1, 67.9, 62.3, 57.5, 47.2, 41.8, 37.6, 28.1,
27.4, 24.5, 19.5; IR (KBr, cm−1
max = 3420, 3250, 3080, 2935, 2850, 1715, 1624, 1580; [Anal. Calcd. for
H
), 6.50 (s, 1H, CH=benzofuran), 7.31–7.03 (m, 4H, Ar
H), 7.38–7.31 (m, 4H, ArH), 8.62 (s,
δ
: 194.7, 181.5, 155.2, 154.6, 139.7, 138.8, 134.9, 129.4, 128.5, 128.3, 127.8,
)
ν
C33H28Cl2N2O3: C, 69.36; H, 4.94; N, 4.90; Found: C, 69.45; H, 5.01; N, 5.05]; LC/MS (ESI, m/z): [M+],
found 572.38, C33H28Cl2N2O3 for 571.15.
(3S)-70-(Benzofuran-2-yl)-5-chloro-60-(4-chlorobenzoyl)-10,60,70,7a0-tetrahydro-30H-spiro[indoline-3,50-
pyrrolo[1,2-c]thiazol]-2-one (5p)
Compound 5p was synthesized according to the general procedure GP2 by reaction of equimolar
amounts of 2e (0.5 mmol, 141 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5 mg), and ((S)-thiazolidine-4-carboxylic
acid 4a (0.5 mmol, 66.5 mg). Yield (453 mg, 85%); faint yellow powder; m.p. 105–106 ◦C; 1H-NMR
(CDCl3)
δ: 3.15–305 (m, 2H, CH2), 3.39 (d, 1H, J = 10.8 Hz, CH), 3.81 (d, 1H, J = 10.8 Hz, CH), 4.09–4.02
(t, 1H, J = 10.4 Hz, CH), 4.49 (t, 1H, J = 8.4 Hz, CH), 4.88 (d, 1H, J = 12.0 Hz, CH), 6.50 (d, 1H, J = 8.8

Molecules 2019, 24, 2342
16 of 20
Hz, Ar
Ar
); 8.75 (s, 1H, NH); 13C-NMR (CDCl3)
128.6, 128.8, 128.5, 128.1, 128.0, 124.3, 124.0, 122.8, 120.7, 111.1, 104.7, 74.6, 71.5, 60.4, 58.9, 55.0, 45.3,
36.9, 29.6, 22.6, 20.9, 14.1; IR (KBr, cm−1
max = 3440, 3250, 3110, 2919, 2845, 1730, 1620, 1580; [Anal.
H), 6.61 (s, 1H, CH=benzofuran), 7.17–7.06 (m, 4H, Ar
H
), 7.41–7.31 (m, 5H, Ar
H
), 7.55 (s, 1H,
H
δ: 194.4, 179.9, 154.7, 154.1, 139.8, 138.9, 134.7, 130.2, 129.3,
)
ν
Calcd. for C28H20Cl2N2O3S: C, 62.81; H, 3.77; N, 5.23; Found: C, 62.90; H, 3.64; N, 5.07]; LC/MS (ESI,
m/z): [M+], found 536.19, C28H20Cl2N2O3S for 535.06.
(3S)-20-(4-Aminobenzoyl)-10-(benzofuran-2-yl)-5-chloro-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro-
[indoline-3,30-pyrrolo[2,1-a]isoindol]-2-one (5q)
Compound 5q was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2f (0.5 mmol, 131.5 mg), 5-Cl-isatin 3a (0.5 mmol, 90.5 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (457 mg, 83%); orange powder;
m.p. 150–152 ◦C; 1H-NMR (CDCl3)
δ
: 1.07–0.79 (m, 5H, CHCH2CH2), 1.43–1.29 (m, 5H, CHCH2CH2),
1.80–1.76 (m, 2H, CH2), 2.08 (t, 1H, J = 5.2 Hz, CH), 3.07 (d, 1H, J = 3.6 Hz, CH), 4.06 (t, 1H, J = 10.8 Hz,
CH), 4.45–4.41 (m, 1H, CH), 5.02 (d, 1H, J = 12.0 Hz, CH), 6.27 (d, 1H, J = 8.4 Hz, Ar ), 6.41 (s, 1H,
CH=benzofuran), 7.16–6.95 (m, 4H, Ar ), 7.35–7.26 (m, 4H, Ar
), 8.64 (s, 1H, NH); 13C-NMR (CDCl3)
: 193.0, 181.9, 175.3, 155.9, 154.5, 151.6, 130.8, 128.4, 127.3, 126.6, 126.1, 113.6, 111.5, 111.1, 103.6, 72.1,
61.6, 57.5, 47.5, 47.2, 41.8, 37.6, 29.7, 29.5, 27.4, 24.5, 19.5; IR (KBr, cm−1
max = 3360, 3230, 3057, 2940,
H
H
H
δ
)
ν
2860, 1720, 1620, 1580; [Anal. Calcd. for C33H30ClN3O3: C, 71.80; H, 5.48; N, 7.61; Found: C, 71.71; H,
5.40; N, 7.50]; LC/MS (ESI, m/z): [M+], found 553.39, C33H30ClN3O3 for 552.20.
(3S)-20-(4-Aminobenzoyl)-10-(benzofuran-2-yl)-10,20,50,5a0,60,70,80,90,9a0,9b0-decahydrospiro[indoline-3,30-
pyrrolo[2,1-a]isoindol]-2-one (5r)
Compound 5r was synthesized according to the general procedure GP2 by reaction of
equimolar amounts of 2f (0.5 mmol, 131.5 mg), isatin 3c (0.5 mmol, 73.5 mg), and (2S,3aS,7aS)-
octahydro-1H-indole-2-carboxylic acid) 4b (0.5 mmol, 84.5 mg). Yield (447 mg, 81%); white powder;
m.p. 155–156 ◦C; 1H-NMR (CDCl3)
δ
: 1.05–0.87 (m, 5H, CHCH2CH2), 1.48–1.37 (m, 5H, CHCH2CH2),
1.85–1.74 (m, 2H, CH2), 2.09 (t, 1H, J = 5.2 Hz, CH), 3.10 (d, 1H, J = 3.6 Hz, CH), 4.09 (t, 1H, J = 10.8 Hz,
CH), 4.48–4.42 (m, 1H, CH), 5.04 (d, 1H, J = 12.0 Hz, CH), 6.29 (d, 1H, J = 8.4 Hz, Ar ), 6.42 (s, 1H,
CH=benzofuran), 7.15–6.91 (m, 4H, Ar ), 7.33–7.19 (m, 4H, Ar
), 8.09 (s, 1H, NH); 13C-NMR (CDCl3)
: 193.4, 181.7, 156.5, 154.6, 151.4, 140.2, 130.6, 128.5, 128.0, 127.1, 124.3, 123.3, 122.4, 121.7, 120.4, 113.4,
110.9, 109.9, 103.0, 72.4, 67.9, 61.4, 57.6, 47.5, 41.7, 37.7, 28.3, 27.6, 24.6, 18.9; IR (KBr, cm−1
= 3386,
H
H
H
δ
)
ν
max
3250, 3060, 2932, 1720, 1620, 1580; [Anal. Calcd. for C33H31N3O3: C, 76.57; H, 6.04; N, 8.12; Found: C,
76.48; H, 5.99; N, 8.00]; LC/MS (ESI, m/z): [M+], found 552.38, C33H30ClN3O3 for 551.20.
4.4. Protocols for the α-Glucosidase Inhibition and α-Amylase Assays
4.4.1. Reagents
α
-Glucosidase type 1 from baker’s yeast (G5003; Sigma-Aldrich, St. Louis, MO, USA), p-nitrophenyl
-d-glucopyranoside (N1377, Sigma-Aldrich), sodium phosphate monobasic (S3139, Sigma-Aldrich),
sodium phosphate dibasic (S5136, Sigma-Aldrich), and acarbose (A8980, Sigma-Aldrich), dimethyl
sulfoxide (DMSO), -amylase from Aspergillus oryzae (Sigma Aldrich), starch, DNS (3,5-dinitrosalicylic
α
α
acid), sodium potassium tartrate tetrahydrate.
4.4.2. α-Glucosidase Inhibition Assay
Sodium phosphate buffer (0.1 M) was adjusted by 0.1 N HCl to pH 7.0 with a pH meter
(Thermo Fisher Scientific Inc., Waltham, MA, USA). p-Nitrophenyl
-glucosidase solutions (1 U/mL) were solubilized in 0.1 M sodium phosphate buffer (pH 7.0). All the
reagents were manufactured shortly before use and warmed to 37 ◦C in a water bath. Sodium phosphate
buffer (0.1 M, 158 L per well) was added to a 96-well plate. -Glucosidase (20 L) and 2 L of
α-d-glucopyranoside (10 mM) and
α
µ
α
µ
µ

Molecules 2019, 24, 2342
17 of 20
sample were added to 20
µL of p-nitrophenyl
α
-d-glucopyranoside. In the 200-µL final reaction volume
(0.02 U/well, 0.1 U/mL) the substrate concentration was adjusted to 10 mM. The background signal due
to the sample color was measured at 405 nm with the PerkinElmer Wallac Victor3 spectrophotometer
(PerkinElmer, Waltham, MA, USA) prior to adding the enzyme. Immediately following
addition, absorbance was measured at 405 nm 8 times at 1 min intervals.
α-glucosidase
4.4.3. α-Amylase Assay
Briefly, 250
10 min at 25 ◦C in one set of tubes. In another set of tubes
phosphate buffer (pH 6.9). 250 L of starch solution at increasing concentrations (0.2–1% (w/v)) was
added to both sets of reaction mixtures to start the reaction. The mixture was then incubated for 10 min
at 25 ◦C and then boiled for 15 min after the addition of 250
L of DNS to stop the reaction. The amount
µL (0.4 mg/mL) of sample was preincubated with 250
µL of
α
-amylase solution for
α
-amylase was preincubated with 250
µL of
µ
µ
of reducing sugars released was determined spectrophotometrically using a maltose standard curve
and converted to reaction velocities.
4.4.4. Calculation of Inhibition Efficiency
The inhibitory concentration 50% (IC50) values were determined from the plots of percent inhibition
versus log inhibitor concentration and calculated by logarithmic regression analysis from the mean
inhibitory values.
4.5. Docking Study
The crystal structure of acrabose bound at amylaose (PDB: ID: 4uac) was obtained from the
Protein Data Bank. The synthesized compounds were prepared for docking via Openeye software.
Before docking, 3D protonation of the structures, running conformational analysis using Omega
commands. Docking results were visualized using the Vida application.
5. Conclusions
A series of new analogues of spiroxindole-integrated benzo[b]furan heterocyclic hybrids were
prepared in good to excellent yield via 1.3-dipolar cycloaddition reactions. The compounds thus
synthesized were assayed for their in vitro α-amylase and
the synthesized analogues, compound 5r carrying an amino group on the aryl ring displayed the
highest inhibition potency for both -amylase enzyme with an IC50 value of 22.61 0.54 M; with
SI: 0.62 and in case of -glucosidase enzyme, with an IC50 value of 14.05 1.03 M with SI: 1.60
compared to the standard drug acarbose ( -amylase: IC50 = 0.75 + 0.07 M; SI: 3.13 and -glucosidase:
IC50 = 2.35 + 0.13 µM; SI: 0.31). In addition, compounds 5a–r showed better activity and selectivity for
-glucosidase than -amylase. Molecular docking studies have shown that compound 5r has good
α-glucosidase inhibitory activities. Among
α
±
µ
α
±
µ
α
µ
α
α
α
binding with the enzyme receptor which coincides with the activities observed. Furthermore, the presence
of an NH2 functionality in these spiropyrrolidine/benzo[b]furan analogues ring makes it a lead compound
for the synthesis of more spiroheterocyclic hybrids with better pharmacological potency.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/12/2342/s1.
(Figures S1–S58 copies from the NMR and IR spectrum).
Author Contributions: Conceptualization, A.B. and Y.Y.; methodology, M.S.A.; validation, A.B.; M.S.A. and
A.M.A.-M.; formal analysis, A.M.A.-M.; investigation, M.S.A.; resources, A.B.; data curation, A.B.; writing—original
draft preparation, A.B.; writing—review and editing, A.B.; visualization, H.A.A.-G.; supervision, A.B.; project
administration, M.S.A.; funding acquisition, M.S.A.
Funding: This research was funded by deanship of scientific research at princess Nourah Bint Abdulrahman University.
Acknowledgments: This research was funded by deanship of scientific research at princess Nourah Bint
Abdulrahman University (Grant No#: 39 - S- 254).
Conflicts of Interest: The authors declare no conflict of interest.

Molecules 2019, 24, 2342
18 of 20
References
1.
Alberti, K.G.; Zimmet, P.Z. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications.
Part 1: Diagnosis and Classification of Diabetes Mellitus; WHO/NCD/NCS/99.2; World Health Organization:
Geneva, Switzerland, 1999.
2.
3.
IDF. Diabetes Atlas, 6th ed.; International Diabetes Federation: Brussels, Belgium, 2014.
Guariguata, L.; Whiting, D.; Hambleton, I.; Beagley, J.; Linnenkamp, U.; Shaw, J. Global estimates of diabetes
prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 2014, 103, 137–149. [CrossRef]
[PubMed]
4.
5.
Marcovecchio, M.; Mohn, A.; Chiarelli, F. Type 2 diabetes mellitus in children and adolescents. J. Endocrinol. Investig.
2005, 28, 853–863. [CrossRef]
Najafian, M.; Ebrahim-Habibi, A.; Hezareh, N.; Yaghmaei, P.; Parivar, K.; Larijani, B. Trans-Chalcone: A novel
small molecule inhibitor of mammalian alpha-amylase. J. Mol. Boil. Rep. 2010, 38, 1617–1620. [CrossRef]
[PubMed]
6.
7.
8.
9.
Al-Zuhair, S.; Dowaidar, A.; Kamal, H. Inhibitory effect of dates extracts on α-amylase and α-glucosidase
enzymes relevant to non-insulin dependent diabetes mellitus. J. Biochem. Technol. 2010, 2, 158–160.
Afonne, O.J.; Orisakwe, O.E.; Obi, E.; Orish, C.; Akumka, D.D. Some pharmacological properties of
Synclisia scabrida III. Indian J. Pharmacol. 2000, 32, 239–241.
Daisy, P.; Jasmine, R.; Ignacimuthu, S.; Murugan, E. A novel steroid from Elephantopus scaber L. an ethnomedicinal
plant with antidiabetic activity. J. Phytomed. 2009, 16, 252–257. [CrossRef]
Shirwaikar, A.; Rajendran, K.; Punitha, I.S.R. Antidiabetic activity of alcoholic stem extract of Coscinium fenestratum
in streptozotocinnicotinamide-induced type 2 diabetic rats. J. Ethnopharmacol. 2005, 97, 369–374. [CrossRef]
10. Akerele, O. Traditional Medicine: Nature’s medicinal bounty; don’t throw it away. World Health Forum 1993
14, 390–395.
,
11. Geethalakshmi, R.; Sarada, D.V.L.; Marimuthu, P.; Ramasamy, K. A-amylase inhibitory activity of
Trianthema decandra L. Int. J. Biotechnol. Biochem. 2010, 6, 369–376.
12. Dewanjee, S.; Das, A.K.; Sahu, R.; Gangopadhyay, M. Antidiabetic activity of Diospyros peregrina fruit:
Effect on hyperglycemia, hyperlipidemia and augmented oxidative stress in experimental type 2 diabetes.
Food Chem. Toxicol. 2009, 47, 2679–2685. [CrossRef]
13. Manna, K.; Agrawal, Y.K. Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-
5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin
analogs. Eur. J. Med. Chem. 2010, 45, 3831–3839. [CrossRef] [PubMed]
14. Zha, X.; Lamba, D.; Zhang, L.; Lou, Y.; Xu, C.; Kang, D.; Chen, L.; Xu, Y.; Zhang, L.; De Simone, A.; et al.
Novel tacrine–benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer’s
disease: Design, synthesis, biological evaluation, and X-ray crystallography. J. Med. Chem. 2015, 59, 114–131.
[CrossRef] [PubMed]
15. Yadav, P.; Singh, P.; Tewari, A.K. Design, synthesis, docking and anti-inflammatory evaluation of novel series
of benzofuran based prodrugs. Bioorg. Med. Chem. Lett. 2014, 24, 2251–2255. [CrossRef] [PubMed]
16. Hiremathad, A.; Patil, M.R.; Chethana, K.R.; Chand, K.; Santos, M.A.; Keri, R.S. Benzofuran: An emerging
scaffold for antimicrobial agents. RSC Adv. 2015, 5, 96809–96828. [CrossRef]
17. Rida, S.M.; El-Hawash, S.A.; Fahmy, H.T.; Hazza, A.A.; El-Meligy, M.M. Synthesis and in vitro evaluation
of some novel benzofuran derivatives as potential anti-HIV-1, anticancer, and antimicrobial agents.
Arch. Pharm. Res. 2006, 29, 16. [CrossRef] [PubMed]
18. Abdelhafez, O.M.; Amin, K.M.; Ali, H.I.; Abdalla, M.M.; Ahmed, E.Y. Design, synthesis and anticancer
activity of benzofuran derivatives targeting VEGFR-2 tyrosine kinase. RSC Adv. 2014, 4, 11569–11579.
[CrossRef]
19. Sashidhara, K.V.; Modukuri, R.K.; Sonkar, R.; Rao, K.B.; Bhatia, G. Hybrid benzofuran–bisindole derivatives:
New prototypes with promising anti-hyperlipidemic activities. Eur. J. Med. Chem. 2013, 68, 38–46. [CrossRef]
20. Bhovi, V.K.; Bodke, Y.D.; Biradar, S.; Swamy, B.K.; Umesh, S. A facile synthesis of bromo-substituted
benzofuran containing thiazolidinone nucleus bridged with quinoline derivatives: Potent analgesic and
antimicrobial agents. Phosphorus Sulfur Silicon 2009, 185, 110–116. [CrossRef]

Molecules 2019, 24, 2342
19 of 20
21. Dawood, K.M.; Abdel-Gawad, H.; Rageb, E.A.; Ellithey, M.; Mohamed, H.A. Synthesis, anticonvulsant,
and anti-inflammatory evaluation of some new benzotriazole and benzofuran-based heterocycles.
Bioorg. Med. Chem. 2006, 14, 3672–3680. [CrossRef]
22. Ashwood, V.A.; Field, M.J.; Horwell, D.C.; Julien-Larose, C.; Lewthwaite, R.A.; McCleary, S.; Pritchard, M.C.;
Raphy, J.; Singh, L. Utilization of an intramolecular hydrogen bond to increase the CNS penetration of
an NK1 receptor antagonist. J. Med. Chem. 2001, 44, 2276–2285. [CrossRef]
23. He, Y.; Zeng, L.F.; Yu, Z.H.; He, R.; Liu, S.; Zhang, Z.Y. Bicyclic benzofuran and indole-based salicylic acids
as protein tyrosine phosphatase inhibitors. Bioorg. Med. Chem. 2012, 20, 1940–1946. [CrossRef] [PubMed]
24. Xie, Y.S.; Kumar, D.; Bodduri, V.V.; Tarani, P.S.; Zhao, B.X.; Miao, J.Y.; Jang, K.; Shin, D.S. Microwave-assisted
parallel synthesis of benzofuran-2-carboxamide derivatives bearing anti-inflammatory, analgesic and
antipyretic agents. Tetrahedron Lett. 2014, 55, 2796–2800. [CrossRef]
25. Galliford, C.V.; Scheidt, K.A. Pyrrolidinyl-spirooxindole natural products as inspirations for the development
of potential therapeutic agents. Angew. Chem. Int. Ed. 2007, 46, 8748–8758. [CrossRef] [PubMed]
26. Yu, B.; Yu, D.Q.; Liu, H.M. Spirooxindoles: Promising scaffolds for anticancer agents. Eur. J. Med. Chem.
2015, 97, 673–698. [CrossRef] [PubMed]
27. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Qiu, S.; Ding, Y.; Gao, W.; Stuckey, J.; Krajewski, K.; Roller, P.P.;
Tomita, Y.; et al. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 2005, 127,
10130–10131. [CrossRef] [PubMed]
28. Ye, N.; Chen, H.; Wold, E.A.; Shi, P.Y.; Zhou, J. Therapeutic potential of spirooxindoles as antiviral agents.
ACS Infect. Dis. 2016, 2, 382–392. [CrossRef] [PubMed]
29. Wade, P.A. The Ganges. In Comprehensive Organic Synthesis; Trost, B.M., Fleming, I., Semmelhack, M.F., Eds.;
Pergmon Press: Oxford, UK, 1991; Volume 4, p. 1111.
30. Sun, Y.; Liu, J.; Sun, T.; Zhang, X.; Yao, J.; Kai, M.; Jiang, X.; Wang, R. Anti-cancer small molecule JP-8g
exhibits potent in vivo anti-inflammatory activity. Sci. Rep. 2014, 4, 4372. [CrossRef] [PubMed]
31. Sun, Y.; Liu, J.; Jiang, X.; Sun, T.; Liu, L.; Zhang, X.; Ding, S.; Li, J.; Zhuang, Y.; Wang, Y.; et al. One-step
synthesis of chiral oxindole-type analogues with potent anti-inflammatory and analgesic activities. Sci. Rep.
2015, 5, 13699. [CrossRef] [PubMed]
32. Jiang, X.; Cao, Y.; Wang, Y.; Liu, L.; Shen, F.; Wang, R. A unique approach to the concise synthesis of highly
optically active spirooxazolines and the discovery of a more potent oxindole-type phytoalexin analogue.
J. Am. Chem. Soc. 2010, 132, 15328–15333. [CrossRef]
33. Barakat, A.; Islam, M.S.; Ghawas, H.M.; Al-Majid, A.M.; El-Senduny, F.F.; Badria, F.A.; Elshaier, Y.A.;
Ghabbour, H.A. Design and synthesis of new substituted spirooxindoles as potential inhibitors of the
MDM2−p53 interaction. Bioorg. Chem. 2019, 86, 598–608. [CrossRef]
34. Barakat, A.; Islam, M.S.; Ghawas, H.M.; Al-Majid, A.M.; El-Senduny, F.F.; Badria, F.A.; Elshaier, Y.A.;
Ghabbour, H.A. Substituted Spirooxindoles. U.S. Patent 9,822,128, 21 November 2017.
35. Islam, M.S.; Ghawas, H.M.; El-Senduny, F.F.; Al-Majid, A.M.; Elshaier, Y.A.; Badria, F.A.; Barakat, A. Synthesis
of new thiazolo-pyrrolidine–(spirooxindole) tethered to 3-acylindole as anticancer agents. Bioorg. Chem.
2019, 82, 423–430. [CrossRef] [PubMed]
36. Barakat, A.; Islam, M.S.; Ghawas, H.M.; Al-Majid, A.M.; El-Senduny, F.F.; Badria, F.A.; Elshaier, Y.A.M.;
Ghabbour, H.A. Substituted spirooxindole derivatives as potent anticancer agents through inhibition of
phosphodiesterase 1. RSC Adv. 2018, 8, 14335–14346. [CrossRef]
37. Lotfy, G.; El Sayed, H.; Said, M.M.; Aziz, Y.M.A.; Al-Dhfyan, A.; Al-Majid, A.M.; Barakat, A. Regio-and
stereoselective synthesis of new spirooxindoles via 1, 3-dipolar cycloaddition reaction: Anticancer and
molecular docking studies. J. Photochem. Photobiol. B Biol. 2018, 180, 98–108. [CrossRef] [PubMed]
38. Lotfy, G.; Said, M.M.; El Sayed, H.; El Sayed, H.; Al-Dhfyan, A.; Aziz, Y.M.A.; Barakat, A. Synthesis of new
spirooxindole-pyrrolothiazole derivatives: Anti-cancer activity and molecular docking. Bioorg. Med. Chem.
2017, 25, 1514–1523. [CrossRef] [PubMed]
39. Scheen, A.J. Clinical efficacy of acarbose in diabetes mellitus: A critical review of controlled trials.
Diabetes Metab. 1998, 24, 311–320. [PubMed]
40. Islam, M.S.; Barakat, A.; Al-Majid, A.M.; Ali, M.; Yousuf, S.; Choudhary, M.I.; Khalil, R.; Ul-Haq, Z. Catalytic
asymmetric synthesis of indole derivatives as novel
350–354. [CrossRef] [PubMed]
α-glucosidase inhibitors in vitro. Bioorg. Chem. 2018, 79,

Molecules 2019, 24, 2342
20 of 20
41. Elshaier, Y.A.; Shaaban, M.A.; El Hamid, M.K.A.; Abdelrahman, M.H.; Abou-Salim, M.A.; Elgazwi, S.M.;
Halaweish, F. Design and synthesis of pyrazolo [3,4-d] pyrimidines: Nitric oxide releasing compounds
targeting hepatocellular carcinoma. Bioorg. Med. Chem. 2017, 25, 2956–2970. [CrossRef] [PubMed]
42. Cockburn, D.W.; Orlovsky, N.I.; Foley, M.H.; Kwiatkowski, K.J.; Bahr, C.M.; Maynard, M.; Demeler, B.;
Koropatkin, N.M. Molecular details of a starch utilization pathway in the human gut symbiont E ubacterium
rectale. Mol. Microbiol. 2015, 95, 209–230. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds 5a–r are available from the authors.
©
2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).